Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001019364 | SCV001180712 | pathogenic | Hereditary cancer-predisposing syndrome | 2019-11-06 | criteria provided, single submitter | clinical testing | The c.944dupG pathogenic mutation, located in coding exon 8 of the SDHA gene, results from a duplication of G at nucleotide position 944, causing a translational frameshift with a predicted alternate stop codon (p.G316Rfs*5). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |
Human Genome Sequencing Center Clinical Lab, |
RCV001537861 | SCV001754797 | likely pathogenic | Paragangliomas 5 | 2020-06-11 | criteria provided, single submitter | clinical testing | This particular SDHA variant, c.944dupG (p.Gly316ArgfsTer5), is predicted to cause a frameshift and subsequent premature stop codon leading to a shortened or absent protein. It is not present in population databases (e.g., gnomAD). Loss-of-function variants in SDHA are known to be pathogenic (PMID: 22974104, 24781757). Therefore, it is considered a likely pathogenic variant. |
Myriad Genetics, |
RCV001537861 | SCV005083659 | pathogenic | Paragangliomas 5 | 2024-05-23 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. |